Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular degeneration.
Kashani AH, Lebkowski JS, Hinton DR, Zhu D, Faynus MA, Chen S, Rahhal FM, Avery RL, Salehi-Had H, Chan C, Palejwala N, Ingram A, Dang W, Lin CM, Mitra D, Martinez-Camarillo JC, Bailey J, Arnold C, Pennington BO, Rao N, Johnson LV, Clegg DO, Humayun MS. Kashani AH, et al. Among authors: palejwala n. Stem Cell Reports. 2022 Mar 8;17(3):448-458. doi: 10.1016/j.stemcr.2022.01.001. Epub 2022 Feb 3. Stem Cell Reports. 2022. PMID: 35120620 Free PMC article. Clinical Trial.
One-Year Follow-Up in a Phase 1/2a Clinical Trial of an Allogeneic RPE Cell Bioengineered Implant for Advanced Dry Age-Related Macular Degeneration.
Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Chen S, Chan C, Palejwala N, Ingram A, Dang W, Lin CM, Mitra D, Pennington BO, Hinman C, Faynus MA, Bailey JK, Mohan S, Rao N, Johnson LV, Clegg DO, Hinton DR, Humayun MS. Kashani AH, et al. Among authors: palejwala n. Transl Vis Sci Technol. 2021 Aug 12;10(10):13. doi: 10.1167/tvst.10.10.13. Transl Vis Sci Technol. 2021. PMID: 34613357 Free PMC article. Clinical Trial.
Capillary density and caliber as assessed by optical coherence tomography angiography may be significant predictors of diabetic retinopathy severity.
Kushner-Lenhoff S, Kogachi K, Mert M, Chu Z, Shahidzadeh A, Palejwala NV, Wolfe J, Itty S, Drenser KA, Capone A Jr, Dugel PU, Moshfeghi AA, Ameri H, Daskivich LP, Wang RK, Kashani AH. Kushner-Lenhoff S, et al. Among authors: palejwala nv. PLoS One. 2022 Jan 26;17(1):e0262996. doi: 10.1371/journal.pone.0262996. eCollection 2022. PLoS One. 2022. PMID: 35081154 Free PMC article. Clinical Trial.
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Aref AA, et al. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. JAMA Ophthalmol. 2021. PMID: 34709363 Free PMC article. Clinical Trial.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
27 results